Biohaven's $795 Million SK Deal Is a Cash Bridge, Not a Growth Story

Biohaven was running out of money. About $270 million in cash as of mid-June. A quarterly burn rate around $125 million. Two or three quarters of runway left, at most.

Then today it announced a $795 million licensing deal with South Korea's SK Biopharmaceuticals for an epilepsy drug candidate called opakalim. The stock jumped over 5%, closing around $14.38.

The headline looks like a growth story. The plumbing is something different: it's a non-dilutive cash bridge dressed up as a pipeline partnership, and the numbers explain why Biohaven needed it.

Biohaven's cash problem has been building for a while. In October 2025, the company warned investors it had less than eight months of runway. It raised $200 million in a public equity offering in November — at $7.50 a share, well below where the stock had traded earlier — and struck a separate $600 million milestone-linked note with a fund called Oberland Capital. That note, tied to Biohaven's ALS drug troriluzole, has been marked up to $259.5 million on the balance sheet and is generating non-cash expenses each quarter as its fair value fluctuates.

None of that stopped the burn. In the second quarter of 2026, Biohaven lost $137 million on revenue of basically zero — it has no products that generate sales. It was spending $100 million a quarter on research and development across multiple programs, and another $24 million on general and administrative costs. With $270 million in the bank at the end of June, the company had maybe one more quarter of reported results before it needed another lifeline.

The SK deal is that lifeline.

Here's how the deal actually works. SK Biopharmaceuticals gets exclusive global rights to Biohaven's Kv7 ion channel platform — led by opakalim, a Phase 2/3 drug candidate for focal epilepsy — in exchange for a payment stream that Biohaven describes as "up to $795 million."

The word "up to" does a lot of heavy lifting here. The near-term cash is $400 million: $350 million at closing and $50 million one year later. On top of that, Biohaven is eligible for up to $150 million in development and regulatory milestones. Those $500 million are what Biohaven actually receives.

The rest of the $795 million number goes to other parties. SK assumed approximately $245 million in milestone obligations to Knopp Biosciences — the company that originally developed the Kv7 platform, which Biohaven acquired in 2022 before Pfizer bought the whole company and then spun off a new Biohaven entity. SK also takes on mid-single-digit royalty obligations to Knopp on sales. So this $795 million figure includes money Biohaven never touches.

After the milestones, SK pays Biohaven tiered royalties on net sales: mid-teens to low-20s percent in the United States and mid-single digits outside the U.S. SK also assumes all future development costs for the program, which is the part that converts this from a simple asset sale into a cash bridge. Biohaven stops writing checks for opakalim.

Then there's what Biohaven keeps. Troriluzole, its ALS drug, which is awaiting an FDA decision and is the collateral behind that Oberland note. A platform of experimental protein degraders in Phase 3 trials. Programs in immunology and oncology. These are the things the $400 million upfront payment buys time for.

The reason the deal makes sense structurally is that Biohaven didn't build the Kv7 platform from scratch. It inherited it. Biohaven acquired the Kv7 platform from Knopp Biosciences in February 2022 — and then Pfizer acquired Biohaven five months later for $11 billion before spinning out a new, shell Biohaven with a blank slate and some of the old pipeline. The Kv7 platform ended up in the new company, but it never became a priority. Biohaven focused its resources on troriluzole and its own degrader programs.

So this is a situation where Biohaven is licensing out a drug it acquired, not one it developed, to buy breathing room for the drugs it actually cares about. That's not unusual in biotech — it's a standard part of the capital allocation game. But the cash timing makes it look more urgent than a typical portfolio optimization.

The deal also works for SK because it fits an existing machine. SK already sells an epilepsy drug called XCOPRI, which was approved in 2019 and has a U.S. commercial organization with over 150 neurology sales reps and direct-to-consumer advertising. Opakalim would be SK's second epilepsy drug. The commercial infrastructure is already built. The question is whether the drug actually works — and that answer comes from clinical trials, not deal economics.

And here's the thing that matters most for the next few months: the pivotal RISE3 trial for opakalim is expected to report top-line results in the second half of 2026. That's the rest of this year. We are in late August.

Biohaven has already completed enrollment in the trial, which began last month. The company has presented earlier data showing opakalim can prolong the time between seizures in a different form of epilepsy — a three-fold improvement in one trial — and has described the drug as having a differentiated tolerability profile because it avoids the sedation and dizziness that plague older epilepsy drugs. But the pivotal focal epilepsy data hasn't been seen yet.

If those results are strong, Biohaven keeps getting milestones and royalties on a drug SK will now commercialize. If they're weak, Biohaven already has the $400 million in its pocket — and that's the point of the structure. The cash comes before the risk resolves.

So what does this mean for someone watching the stock?

The deal solves the near-term cash problem. $400 million, added to roughly $270 million in existing cash, gives Biohaven more than enough runway to reach the RISE3 readout and, assuming a positive result, continue developing its own programs. It's non-dilutive — no new shares were issued. That matters because Biohaven has already diluted shareholders significantly: the share count went from about 102 million in mid-2025 to roughly 151 million by mid-2026, and the November offering was priced at a steep discount to the stock's prior range.

The deal also removes one risk from the pipeline. Opakalim was going to be a binary event either way — the RISE3 trial could fail regardless of who pays for development. The difference now is that Biohaven gets paid whether it succeeds or not. The milestones and royalties are upside, not the foundation.

But the foundation of this stock remains troriluzole. That ALS drug is the collateral behind the Oberland note, and its FDA outcome determines whether Biohaven becomes a commercial company or stays a clinical-stage one burning cash and hoping for the next catalyst. The SK deal doesn't change the troriluzole timeline, the Knopp obligation, or the fact that Biohaven generates zero revenue.

It does change one thing: Biohaven now has time to find out.